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ABSTRACT

Forty eight patients with previously untreated diffuse histiocytic*lymphoma
(DHL) were treated

prospectively with ACOMLA (hydroxydaunorubicin,

cyclophosphamide, vincristine, methotrexate with leucovorin,
arabinoside)
prednisone,

or CHOP-B (cylophosphamide,
and bleomycin).

hydroxydaunorubicin,

Forty six of

7

immunoblastic,

immunoblastic,

8 T-cell

large non-cleaved

identification of 13 large cleaved
follicular center cell,

and 4 large cell

68% and CHOP-B 71%).

Of

patients have relapsed.

these,

70%

was not significant.

symptoms were not

ACOMLA caused

Drug

response

slightly more sepsis but

Patients with follicular center cell

Age,

rate of

sex,

stage,

types) appear

Median survival

toxicity was substantial with
the difference

(FCC)

immunoblastic

lymphomas had
sarcomas

found between the cleaved and
site of

involvement,

significantly correlated with survival.

sarcomas (B and T cell

treatments.

Median follow-up time is 32 months.

No difference in survival was

non-cleaved FCC types.

lymphomas.

4 of the ACOMLA patients and 3 of the CHOP-B

a significant survival advantage over patients with
(p=0.01).

two

(with ACOMLA having a

for all patients has not yet been reached.
3 drug related deaths.

14 B-cell

unclassified

There was no difference in survival advantage between the
Overall complete response rate was

vincristine,

these patients were classified

by the Lukes-Collins classification with the
follicular center cell,

and cytosine

or

presence of

Immunoblastic

to be more resistant

to current

chemotherapeutic regimens and may warrant more aggressive

treatment.

.
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INTRODUCTION

The Non-Hodgkin's

lymphomas

(NHL) are a diverse group of neoplasms*of

lymph nodes and lymphoid components of other
these disorders has paralleled

tissues.

any disease should be 1)
accurate,

and 4)

easy to use,

prognostically and

2)

since

they were

Ideally,

reproducible,

the classification of
3)

theme of

scientifically

This paper will present a brief history of

fifty years

the development of

classifications of non-Hodgkin's lymphomas as an introduction
study done at Yale between May,

1976 and April,

prospective randomized

two different chemotherapeutic

of

the most aggressive of

lymphoma.

This

trial was

be made on the ability of

the non-Hodgkin's
performed

treatment so

1982.

This

the

to a report

of a

study is a
regimens

for one

to allow implications

the Lukes-Collins classification (of

that a more efficacious

ago.

lymphomas - diffuse histiocytic

in such a way as

identify subsets of diffuse histiocytic

The

research done on these

first described one hundred and

trial of

them and has

therapeutically significant.

production of such a scheme has been the
neoplasms

The classification of

the scientific understanding of

been a source of controversy for many years.

the

lymphoma

that are

the NHL)

refractory

treatment can be designed

for

to

them.

to

to

2

GENERAL HISTORICAL BACKGROUND

Interest

in the nature of

lymphomas

is generally considered

in 1832,

(though some will cite

Morgagni

in 1779), with a published report by the now-famous Thomas Hodgkin

entitled

"On some morbid appearances of

(1).

In this report,

the work of Malpighi

to have begun

Hodgkin presented

that

"as

the clinical

far as could be ascertained

could be collected
appeared

an irritation
texture

propagated

condition of

the spleen which was,

in a

with defined bodies of various

sizes

diseased glands" and

that

concluded

derangement of

the glands and

involvement of

the

nodes

rather

surface or other

vessels."

few of

the

to

He

the

"thickly pervaded
that of the

believed

that

involvement of

"and on this account may not always have been produced,

[derangement]

inflamed

"close connection between

spleen".

spleen was a secondary event

result of

Hodgkin also noted

the cases,

there was a

the glands

than the

in structure resembling

that of

or from what

this enlargement of

those bodies,

their inferent

spleen"

features and pathologic

from observation,

to them from some ulcerated

through the medium of

the

of

lymphadenopathy and splenomegaly

from the history of cases,

to be a primitive affection of

that

the absorbent glands and

appearance of seven patients with generalized
stating

in 1661 or

of the glands or some other disease carried off

the

the

the
lymph

when that
the patient"

(1).
This work by Hodgkin seems
Sir Samuel Wilks.
disorder

Wilks

to have been largely ignored

the work of

published a report of 15 patients with a similar

"thirteen of which resembled

Hodgkin first brought

until

under

in all particulars...[those]

the notice of

the

profession"

(2).

which Mr

Wilks noticed

3

\
that

this disease represented a distinct and

among all of the other afflictions of
noticed

the

"remarkable anemia" and

from leukemia.

Finally,

it

lymph nodes and spleen.

is clear that he

in an act of chivalry,

name in history by naming
Before

the

the disorder

the work of Wilks,

remained until 1893 for Kundrat

It

remained,

in order

known at

calling

it

as well as

(3).

time

to be a disease

"lymphosarcoma"
for

(4).

It

the

from "aleukemic

from

"lymphogranula",

and a number of other synonyms for Hodgkin's disease

however,

until 1902 for Dorothy Reed

to describe

still a medical

and develop histopathologic criteria

Hodgkin's disease,

that

to distinguish it

multinucleate giant cells (while she was
bear her name,

disease

to develop histologic criteria

leukemia" another term coined by Virchow,

(5).

this disease

the German pathologist Virchow too had

of the peripheral blood and bone marrow,

diagnosis of lymphosarcoma,

separated

He also

he preserved his predecessors

"Hodgkin's"

distinguished this disorder from leukemia,

"lymphogranulomatosis"

separate pathological condition

for

the

student) which now
the diagnosis of

which was felt to be a separate clinico-pathologic entity

(3,6).
In 1926,

Fox went back to

the original material preserved by Hodgkin and,

using the criteria developed by Reed and Sternberg,

confirmed

Hodgkin's disease in only three of the original seven cases
presence of a separate
two kinds of
cells,
these

and

"non"-Hodgkin's

"lymphosarcoma”:

lymphoma

(7).

Ewing,

"malignant lymphosarcoma"

"reticulum cell sarcoma" composed of

the diagnosis of

thus confirming the
in 1928,

composed of smaller

larger ones.

He believed

tumors arose from either reticulum cells or from lymphocytes

germinal centers of lymph nodes

(8).

Two years

described

in the

later Roulet published

that

'

4

criteria

for

time that

the diagnosis of

Brill described a group of

which were radiosensitive and
This

"reticulum cell sarcoma"

"Brill-Symmer's" disease after
during

lymphomas

giant

technology),
reproduce,

it

and,

(NHL)

this

prognosis*(10).

lymphoma"

Brill

proved
other

While

this

to be of
than

the

provided

into

or

(11).

three groups based upon microscopic

lymphoma (or synonyms),

the disease at

follicular lymphoma,
(12,13).

the work of N.E.

follicular

reticulum cell sarcoma.
understanding of

follicular

it was at

the early part of this century pathologists generally divided

the non-Hodgkin's
architecture;

"giant

and

"follicular" architecture

thus had a relatively benign

lymphoma came to be called

Thus,

lymphomas with

(9),

that

lymphosarcoma,

loose classification represented
time

limited

(as well as

usefulness as

the best
it

in

the way of

the best

in histologic

was difficult

relatively benign prognosis of
little

and

prognostic

to

the giant
information'

.

5

Rappaport Classification

In spite of its limited usefulness,

this classification scheme persisted

until the early sixties when a classification developed by Rappaport, Winters,
and Hicks, came into general use.

These pathologists believed that a

classification scheme should be based primarily on cytologic grounds (i.e. cell
types) with a secondary emphasis on architecture (14).
published in 1956, further modified in 1966 and 1978

Their system,

(15,16),

first

proposed five

groups of NHL (see table 1) divided by cell type (lymphocytic, histiocytic, or
mixed lymphocytic-histiocytic) with each cell type showing two types of
architecture;

"nodular" where the lymphomatous cells are clustered around in

discrete identifiable nodules or "diffuse” where the lymphomatous cells have
spread to the point that they totally efface the underlying nodal structure.
The lymphocytic groups are further modified by whether the cells are well or
poorly differentiated.

Table 2 shows the Rappaport classification in relation

to the system that preceded it.

The latest version of the Rappaport

classification is shown in Table 3, and Figure 1 illustrates the essential
morphologic characterizations.
Since its original publication in 1956, numerous studies have confirmed
Rappaport's original assertion that, within each cell grouping, a lymphoma with
a nodular (follicular) architecture confers a better prognosis than one with a
diffuse pattern and that a lymphoma composed of lymphocytes, regardless of
degree of differentiation, confers a better prognosis than a lymphoma composed
of either mixed cells or histiocytes (14,16-21).
provide valuable prognostic information,

Having thus been proven to

the Rappaport classification

6

gained wide acceptance and became

the classification that was used in clinical

trials world-wide.
However, during the late sixties and early seventies new information was
being discovered about

the

structure,

function,

and maturation of lymphocytes

that began to cast doubt upon the scientific accuracy of
classification,
include

but

which was based upon morphologic criteria alone,

the new immunologic

histiocytes of
rather

addition,

the Rappaport

terminology.

It was

shown,

the Rappaport classification were not

for example,

indeed

"true"

studies were published

that

indicated

that

discoveries and others

it became apparent

immune system.

histiocytes

classification scheme resulted

classifications which confounded clinician and

there remained

no less

As

the dust

From these

the

"conceptually relevant"
"new-improved"

researcher alike and

settled,

however,

than six classification schemes

left

These systems are

(in alphabetical order):

The

Lymphoma Investigation (BNLI)

classification,

Lukes-Collins classification,

the Kiel classification,

classification,
While
beyond

and

the

it became clear
(excluding minor

modifications) with the proponents of each claiming superiority over
others.

that a

include modern

in a veritable explosion of

mere student hopelessly lost.

In

to researchers at many centers

The search for

the

nodular lymphomas appeared

classification scheme needed to be developed which would
concepts of the

not

that

transformed B-lymphocytes which resembled histiocytes (22).

to be uniformly composed of cells of B-lymphocyte origin (23).

that

and did

the

British National

the Dorfman classification,

the

the Rappaport

the World Health Organization classification (24-27).

the details of

the BNLI,

the scope of

this paper,

Dorfman,

Kiel,

and WHO classifications

the general outline and

each will be given after a description of

salient

are

features of

the Lukes-Collins classification.
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Figure

Rap pa pc r t 0 ) a s s i i i c a I.

UNDIFFERENTIATED
LYMPHOID CELL
LYMPHOCYTIC
DIFFERENTIATION

H LSTIOCYTIC
DIFFERENTIATION

WELL
DIFFERENTIATED

POORLY
DIFFERENTIATED

- dark staining
round nucleus

- indented nuclei

HISTIOCYTIC CELLS
- large cell size
- pleomorphic nuclei

- scanty cytoplasm

- prominent nucleoli

(adapted

from J.

Waldron handout lo/fio)
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Table

1.

RAPPAPORT CLASSIFICATION (Original)

Nodular or Diffuse
Well-differentiated Lymphocytic
Poorly-differentiated Lymphocytic
Mixed Lymphocytic-Histiocytic
Histiocytic
Undifferentiated

(Adapted

Table 2.

from Rappaport

RAPPAPORT CLASSIFICATION AND

Rappaport

••OLD" TERMINOLOGY

Old Terminology

Nodular lymphomas - Giant
(all cell

(14))

Follicular Lymphoma

types)

Diffuse Lymphomas
Lymphocytic

- Lymphosarcoma

Mixed

- Reticulum Cell Sarcoma

Histiocytic

- Reticulum Cell Sarcoma

Undifferentiated - Reticulum Cell Sarcoma

(Adapted

from Rappaport

(14))

9

Table 3.

RAPPAPORT CLASSIFICATION (UPDATED) WITH FREQUENCY OF OCCURENCE

Approx.

% of total

NODULAR LYMPHOMAS

1

Lymphocytic,

Well-differentiated

19

Lymphocytic,

Poorly-differentiated

8

Mixed,

2

Histiocytic

Histiocytic and Lymphocytic

DIFFUSE LYMPHOMAS
4

Lymphocytic, Well-differentiated
(+ plasmacytoid features)

9

Lymphocytic,

Poorly-differentiated

(+ plasmacytoid

8

Lymphoblastic,

5

Mixed,

28

(+ convolutions)

Histiocytic and Lymphocytic

Histiocytic

2

features)

(+ sclerosis)

Undifferentiated

(Burkitt's and

non-Burkitt's)
15

UNCLASSIFIED

100

(Adapted

from NCI sponsored

study of NHL (23))
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The Lukes-Collins Classification

The classification scheme for
1974,

subsequently modified in 1975 and 1976

attempt

to

(28-32),

was

incorporate concepts of modern immunology.

It

those most widely used
and Collins based

in the U.S.

according

to

but

it

is not without

their system on the premise

lymphoma are neoplasms of

the

immune system,

their B or T cell origins.

in their own and in other’s
and

the NHL proposed by Lukes and Collins

that,

the

first

is currently one of
its critics.

since

to

Lukes

the malignant

they should be classified

They based

laboratories,

one of

in

their work on studies done

which traced

the normal development

transformation of lymphocytes under antigenic or mitogenic stimulation.

Comparing this normal development with cytologic patterns
tissue,

Lukes and Collins proposed that malignant

"block" or "swtich-on"

(or derepression)

in lymphomatous

lymphomas develop from a

in the normal

transformation of

lymphocytes (30).
Tracing

the normal

transformation of a lymphocyte,

or mitogenic stimulation,

the cell can be seen to undergo

of development which take place within the germinal
follicular center).

First,

called
stains.
cell

to

At

slightly and

this

(sclFCC).

and is
stage,

(It

a different context

This

the

its

the nuclear membrane which causes

take on a bilobate or multilobate appearance.

"cleavage"

four distinct phases

follicle (also called

the stimulated B-cell grows

nucleus develops a sharp infolding of
nucleus

either under antigenic

the

infolding is

readily apparent under light microscopy with normal
the cell

is called a

should be noted here
than previously.

that

Here

small cleaved follicular center
the word

"follicular"

"follicular"
refers

is used

to a location

in

11

within a lymph node whereas
classification,
architecture.

"follicular"

referred

It will be seen that

on a "follicular"
the lymphomas,

architecture.

the word

in

the discussion of

"follicular" center cell

As

to architecture.)

cleavage,

to become,

the Rappaport

to a particular type of nodal
lymphomas

can take

this has been known to confuse students of

"nodular" will be used

referring

cell

previously,

instead of

The cell then continues

appropriately enough,

a

"follicular" when

to grow,

retaining

its

large cleaved follicular center

(lclFCC).
At

this point,

the cell begins

to show signs of mitotic activity,

affinity for pyronin stain (pyroninophilia)
synthesis,

and

cell develops prominent nucleoli and
follicular center cell (IncFCC),
size of a non-stimulated
In

the cells engaged

(sncFCC).

and can grow to as

it

is apparent

Transformation of

place outside the

that

large as

four

the

times

the

follicle

the non-cleaved cells are

the cleaved cells

the

stimulated

represent

it undergoes

The

the

transformation into

The cell becomes markedly pyroninophilic,

nucleus and many prominent nucleoli become visible.

their

lymphocyte continues

in the interfollicular area where

cell becomes an even more avid replicator as
an immunoblast.

Growth continues as

the cell is now called a large non-cleaved

in active replication while

quiescent counterparts.

The cell is now called a

lymphcyte.

this normal development

but now takes

indicating an increase in protein

the nuclear cleavage disappears.

small non-cleaved follicular center cell

with mild

develops a larger

immunoblasts

proliferate into daughter cells which become either the antibody-producing
plasma cells or small

"memory"

lymphocytes.

transformation are depicted in Figure

2.

These events

in the normal

B-cell

12

Figure 2.

B and T Ceil Trane format ion

large cleaved

small non-cleaved

lendritic
ticulum cell

FOLLICULAR
CENTER

B-CELL
immunoblast (B-Cell)

\

post follicular
memory B-cell

plasma cell

T-CELL
convoluted
T - lymphocyte

(adapted

immunoblast

from J.

(T-Cell)

Waldron handout 10/80)
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Small T-cell

lymphocytes also have

transformation but do so outside

the

potential of undergoing blast

the germinal

area and do not develop nuclear cleavage.
lymphocyte
called

to

immunoblast,

then that

Instead,

parafollicular

they pass

from*

lobulations which is

(33).

lymphomatous development

derepression in the normal pattern of lymphocyte
Collins proposed

as

in the

they develop multiple nuclear

"chicken-footprinting"

Believing

follicles

nine different categories of

block at a particular point of development.

represents a block or
transformation,

Lukes and

lymphomas each corresponding
This

is

to a

shown schematically with

the lymphoma categories superimposed upon normal development

in Figure 3.

formal Lukes-Collins classification is listed

will be described

in Table 4 and

The

briefly.

B-Cell Lymphomas
Small B-cell Lymphoma;
differentiated
in Figure 2.

lymphoma is composed of small,

lymphocytes which appear like
The appearance of nodes

is indistinguishable
(CLL) and

This

indeed

lymphocytes

from patients with small B-cell

from those of patients with chronic

lymphocytic

shown

lymphomas
leukemia

this disease often develops a leukemic component.

Plasmacytoid Lymphocytic Lymphoma:
to

the unstimulated

well-

the small B-cell lymphoma but

different point and

This

is believed

lymphoma has a

to arise from a block at a

the cells contain plasmacyte

Follicular Center Cell Lymphomas:
follicular center origin,
follicular center cell

similar appearance

features.

Composed of

transformed B-cells with a

these lymphomas contain all variants of

(FCC);

cleaved and

non-cleaved,

small and

the
large.

They

14

can be

found with or without

and Collins place no
lymphoma.
represent

It

is

sclerosis.

It

is

important

to

significance on the nodular or diffuse

felt

that

the nodular

forms of

that Lukes

nature of a FCC

the FCC lymphomas mer'ely

the disease caught at an earlier stage before

efface the normal nodal architecture and become

stress

it has grown enough to

"diffuse"

in appearance.

FCC

lymphomas are found which contain mixed cleaved and non-cleaved cells but Lukes
and Collins do not have a category for a
Instead,

"mixed"

cleaved-non-cleaved

a FCC lymphoma is defined as non-cleaved

if

the node is

"focally

dominated by non-cleaved cells or the number exceeds 25% throughout"
Immunoblastic Sarcoma
non-cleaved cells,
than the

(B-Cell Type):

(31).

lymphomas are composed of large-

which are larger and have a more pyroninophilic cytoplasm

large non-cleaved cells of

lymphomas of the

These

lymphoma.

fully transformed

the

follicular center.

lymphocyte or

They represent

immunoblast.

T-Cell Lymphomas
Small T-Cell Lymphoma:
of the

The

small B-cell lymphoma.

logically it is similar to
be distinguished

small T-cell
It,

too,

the B-cell

lymphoma is

is associated with CLL.

lymphoma but has

Morpho¬

features by which it may

(34).

Sezary Syndrome - Mycosis Fungoides:

Included here for completeness,

disorders have been proven to be of T-cell origin.
lymphomatous disorders confined

to

They are,

these

however,

the skin and have a very different natural

history than the other lymphomas discussed here.
further.

the T-cell counterpart

They will not be dealt with

’

15

Convoluted Lymphocyte:

These lymphomas are composed of

partially

transformed T-lymphocytes which display the lobulation referred
footprinting”.

to as

"chicken

They are easily confused with small cleaved FCC but c^n be

differentiated by the presence of these

lobulations.

Convoluted

lymphomas are commonly associated with a thymic mass and

lymphocyte

leukemic

transformation.
Immunoblastic Sarcoma (T-Cell Type):
immunoblastic

sarcoma,

this lymphoma is a pleomorphic diffuse lymphoma with

commonly a mixture of small and

transformed

is common as is a pale cytoplasm.
significantly from one case

lymphocytes.

Nuclear irregularity

The mean tumor cell size varies

to another.

would be classified as Rappaport
included

The T-cell counterpart of the B-cell

Some of

"histiocytic"

the T-immunoblastic

sarcomas

lymphomas while others would

be

in the mixed cell category (33,34).

Histiocytic Lymphomas:

Unlike

the Rappaport classification which

identifies a larger number of "histiocytic"
classification a lymphoma of
Lukes and Collins'

lymphomas,

"true" histiocytes

in the Lukes-Collins

is rare,

occurring in one of

early studies only in one case of three hundred

reviewed.

Identified by their large size in the Rappaport classification, most
"histiocytic”

lymphomas turn out

(see Table 5).

Unidentified

The

to be composed of large FCC or of immunoblasts

prognostic significance of

this will be discussed

(U-Cell)

Lukes and Collins deemed a lymphoma to be a U-cell
any surface markers by which it could be
according

to

later.

them,

is

identified.

"...hypothetical and

lymphoma when it
The U-cell group,

provides a group for

those

lacked

•
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proliferations of lymphocytes
detectable"

(35).

that

prove

to have no discriminating cell markers

It essentially provides a

been the object of

"wastebasket”

category and has

some criticsm.

Unclassifiable
The

"unclassifiable”

group "...allows

categorization of those processes

that are technically unsatisfactory for precise cytologic classification but
are sufficient
recent

for identification of

study by the NCI,

"unclassifiable"
category for

the process as lymphomatous"

37% of routinely prepared

slides were

by the Lukes-Collins system whereas

the other classification systems

ranged

the

(32).

found

to be

"unclassifiable"

from 15-30%

In the

(24).
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Table 4.

LUKES AND COLLINS CLASSIFICATION

T-CELL TYPES
Small Lymphocytic
Sezary-Mycosis Fungoides
Convoluted Lymphocytic
Immunoblastic Sarcoma of T-Cells

B-CELL TYPES
Small Lymphocytic
Plasmacytoid Lymphocytic
Follicular Center Cell,

small cleaved*

Follicular Center Cell,

large cleaved*

Follicular Center Cell,

small non-cleaved*

Follicular Center Cell,

large non-cleaved*

Immunoblastic Sarcoma of B-Cells
Histiocytic

UNDEFINED

UNCLASSIFIED

*may be nodular,

nodular and diffuse or diffuse,

with or without

(adapted

sclerosis

from NCI sponsored

study of NHL (24))
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Figure 3.

Lukes-Collins Classification*
Relation to normal transformation

large cleaved

small non—cleaved

large cleaved
small cleaved

Follicular Center
Cell (FCC)
Lymphomas

Small B-Cell
Lymphocytic
Lymphoma

Small T-Cell
Lymphocytic
Lymphoma

B-Immunoblastic
Sarcoma

Convoluted
T-Cell Lymphoma

(adapted

T-Immunoblastic
,arcoma

from. J.

Waldron handout 10/80)
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Prognostic Significance of Lukes-Collins Classification

Since one of the aims of a classification system is to provide som&
information about prognosis,

the value of a system must be questioned, no

matter how "scientifically accurate" or "conceptually relevant" it is, if it
does not provide this information.

This has been one of the more controversial

points concerning the Lukes-Collins classification.

Based as it is on presumed

"blocks" or "switch-ons" in the path of normal lymphocyte transformation, it is
tempting to assume that as one progresses from lymphomas composed of small
non-transformed B-cells, which are mitotically inactive in their normal state,
to lymphomas composed of immunoblasts, which in their normal state are poised
ready to produce daughter cells,
neoplasms (32).

there would be a trend toward more aggressive

Generally, this has been proven to be the case.

Small B-cell

lymphomas have a better prognosis than FCC lymphomas which, as a group
(including large and small cells), have a better prognosis than immunoblastic
sarcomas. (35).
There has been, however, some disagreement over the prognosis of the large
cell groups:

large FCC cleaved and non-cleaved, and the immunoblastic sarcomas

(both B and T cell origin).

Most studies indicate that the prognosis for the

immunoblastic sarcomas is worse than that of the large cell FCC lymphomas (27,
31,35-38) although this is not a universal finding.
year retrospective review,

Garvin et.al. (26) in a 22

found that there was no significant difference

between the FCC and the immunoblastic sarcomas, although there appeared to be a
trend toward a better prognosis for the FCC lymphomas.

This study, however,

was a retrospective review where the patients received heterogeneous therapy
and experienced generally poor survival.

There seems to be more disagreement

.
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over the prognosis of the other two large cell groups,
and

the FCC large non-cleaved.

series of 66 patients
section on treatment
was

that

One study by Strauchen et.al.

for an explanation of

non-cleaved FCC group (p<0.01).

et.

al.

these acronyms).

analyzed a

than

Their conclusion
the

(38) and a retrospective review by Barcos et.al.

reported in 1978

(28)

large

This conclusion is supported by a prospective
(45).

Nathwani

a retrospective review of 202 cases of DHL in

which the large cleaved FCC lymphomas had a better prognosis.
recently they reported another series of 162 cases

However,

more

in which they found no

difference in survival between any of the Lukes-Collins
(64).

(36)

prospectively treated with either C-MOPP or BACOP (see

the large cleaved FCC had a better prognosis

study by Stein

the FCC large cleaved

subtypes of

the DHL

Armitage reported a series of patients (n=31) uniformly treated with

CHOP in which the patients with large non-cleaved lymphomas did better
patients with large cleaved ones
no difference between the

(37).

Garvin's

(26)

than

retrospective study noted

two groups.

Comparison of Rappaport and Lukes-Collins Classifications

Table 5 shows

the rough correlations between the Rappaport and Lukes-

Collins classifications.
fact
while

that

the

The most obvious difference between the

former groups

the latter groups

them around

architecture

(nodular vs.

significance

in numerous

architecture because

it

the lymphomas around cell

studies,

to be of

While

prognostic

Lukes and Collins have not emphasized

is not relevant

the

type and architecture

their immunologic origin.

diffuse) has been shown

two is

in light of modern discoveries

in

21

Immunology.

As

it was

stated before,

and diffuse lymphomas do not
reflect,

Lukes and Collins believe

represent different clinical entities but rather

within a given cell type,

nodular lymphomas representing

different

of

the

defines

second major difference between the
"histiocytic"

the histiocyte by its

the other hand,
and divides
5):

lclFCC,

"true"

lymphoma.

stresses

histiocytic

with

the nodal architecture.
two classifications

large size.

is

in the area

The Lukes-Collins classification,

the relative rarity of

Immunoblastic

lymphoma.

the same disease,

The Rappaport classification essentially

the Rappaport histiocytic
LncFCC,

stages of

the early stages of the disease before the

lymphomatous cells have spread and effaced
The

that nodular

lymphomas

sarcoma

on

"true" histiocytic lymphomas
into

five subgroups

(see Table

(both B and T cell derived),

and
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Table 5.

COMPARISON OF LUKES-COLLINS AND RAPPAPORT CLASSIFICATIONS

RAPPAPORT

LUKES-COLLINS

Nodular and/or Diffuse

* Well Differentiated
** Poorly Differentiated
*** Lymphocytic/Histiocytic
(Adapted

from Lukes and Collins (30))
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Criticism of the Lukes-Collins Classification

While Lukes and Collins have been widely praised
modern understanding of
the lymphomas,
well-cited

lymphoid

the NHL comparing

Rappaport classification,

its critics.

the Lukes-Collins

scheme

for

In a

classification with

the authors (Rappaport being among

the LCC along a number of lines.

them)

the

criticized

They reviewed a series of 202 cases of NHL

and classified them according to both systems and correlated
data

introduced

physiology into a classification

their classification is not without

study of

for having

this with survival

(28).
First

these authors found

it difficult

to categorize malignant

into separate B and T cell groups on a morphologic basis alone.
T-cell or B-cell can often be assumed or inferred
features and patterns of growth,

there

"While

for use

is no conclusive evidence

in clinical

the

from certain cytologic

number of cases in which this can be done is sufficiently large
classification suitable

lymphomas

programs"

(28).

that

the

to make

this

This criticism is

further supported by the recent NCI study in which 37% of routinely stained
lymphomas were
(compared

to

Jaffe et.al.

found

to be unclassifiable by the Lukes-Collins

15-30% for
has

the other classifications)

similarly

(24).

found difficulty in predicting

classification

A third

study by

immunologic

by morphologic criteria alone

(44).

predict

in 61% of 29 cases of diffuse aggressive

immunologic phenotype

Non-Hodgkin's

phenotype

These authors were only able to correctly

lymphomas.

The second criticism stated
proposed by Lukes and Collins.

in

this

paper concerns

The U-cell category,

the

"U-cell"

they claim,

class

is difficult

,

.
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to comprehend or elucidate.

If

the U-cell

is defined by lack of

surface marker

then it becomes a heterogeneous group that can have little predictive value,
and

thus Lukes and Collins have

They claim

that more

since

term which

is at best,

than thirty percent of histiocytic

cell markers and would
that,

introduced a

thus be classified as U-cell.

in rare cases any morphologic

ambiguous.

lymphomas do not have

In addition,

they claim

type of NHL may lack surface markers,

there is no consistent correlation between morphology and

immunology in

the

U-cell category (28).
Another major criticism that has been cited against
classification is
the

lymphomas.

the lack of emphasis

the Lukes-Collins

placed upon the architectural

Nathwani et al separated

their cases by both Lukes-Collins

classification as well as by architecture and compared survival
they found was

that within each Lukes-Collins class,

conferred a better prognosis.
conceptual
included

relevance

Thus,

they claim that

it does provide prognostic

in any classification scheme

(28).

recently in the National Cancer Institute
NHL which will be discussed
between nodularity and

later.

survival

Nathwani has also criticized
that

into

study

they claimed

but

nodularity has no

is

should be
supported more

find

type

(24).

to separate

thus question its ultimate usefulness.

stating

the histiocytic lymphomas

that

found no difference among

that it was difficult

the

too showed an association

the Lukes-Collins classification by

They did

What

the classifications of

independent of cell

five categories.

lymphomas did better,

even if

This conclusion

study of

times.

nodular architecture

information and

they found no apparent significance in dividing

of Rappaport

and

This

pattern of

the

large cleaved FCC

the rest.

In addition,

this group by morphology alone

Recently however,

a study by
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Van der Valk et.

al.

(39)

investigated

morphometric cell parameters alone,

this

problem and concluded

including nuclear size and

that by using

shape,

cytoplasm

t

area,

and cytoplasm

to nucleus ratio,

non-cleaved FCC lymphomas

from the

it was

possible

immunoblastic

to

separate

sarcomas and

the

large

from "true"

histiocytic lymphomas.
In

the most

recent

paper by Nathwani

et.

al.

(64)

the authors did not

specifically comment on the difficulty they encountered
the Lukes-Collins classification.
found

to be of suboptimal

the cases used
in 129 of 162

technical quality

in the study a consensus was
(80%).

significant difference

59 out of 279

(21%)

cases were

reached

found,

Of

regarding subclassification
(23,37) which

the Lukes-Collins classification.

in survival was

the DHL by

for precise subcalssifications.

This corresponds with other studies

reported on the reproducibility of

any of

However,

subdividing

using these 162 cases,

the 5 Lukes-Collins subdivisions of diffuse histiocytic

No
between

lymphoma.

'
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Other Classifications

Dorfman Classification:

Proposed

first

is a compromise between the Rappaport,
classifications and
terminology,

Lukes-Collins,

represents an attempt

such as

"histiocyte".

in 1974,

the Dorfman classification
and

the BNLI

to eliminate controversial

Like that of Rappaport,

the Dorfman

classification makes a distinction on the basis of architecture and does not
use B and T cell

terminology (40).

BNLI Classification:

Proposed in 1973,

the BNLI classification is

essentially a modification of the Rappaport system that
follicular center origin of nodular

lymphomas.

two grades:

prognosis,

Grade I,

lymphomas and

with a better

WHO Classification:

those that are

It

is

"...subject

to

comprised of
(41).

the World Health Organization is
limited

understanding of

the

further modification as new knowledge
the tumor cells"

(42).

This

Proposed by Lennert and his collaborators,

classification is widely used
but uses

in Europe.

the words

what Lukes and Collins call

"centrocyte" and

"cleaved" and

the Kiel

This system does not separate by B or
"centroblast"

"non-cleaved"

to refer

to

cells respectively.

The Kiel classification groups the NHL by two grades of malignancy:
Low (43).

the

the NHL by architecture.

Kiel Classification:

T cell origin,

into

the nodular

and Grade II,

on our current

accumulates on the precise origin of
classification groups

the

the NHL also

poorly differentiated

The classificaton of

acknowledged as a compromise based

separates

comprised of

the more well-differentiated ones,

histiocytic lymphomas and

lymphomas.

It

recognized

High and
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The NCI Sponsored Study of the Classifications of the Non-Hodgkin's Lymphomas

It

should now be apparent how this explosion of

classifications,
was able

while indeed

"definitive”

providing useful information and

to confuse even the most dedicated physician.

classificatons (and

just as many minor ones)

fuel

for debate,

With at least six major

it became difficult

for the

average physician to interpret the literature on the NHL and compare studies
done at different centers using different classification.
In

1981

confusion.
presented

the NCI sponsored a study in an attempt
Taking pathologic material

to each of six

classifications.

The

to eliminate some of this

from 1175 cases of NHL,

slides were

"experts" who were proponents of one of

slides were also presented

pathologists not connected

to six

the major

"experienced"

to a particular classification.

Each pathologist

reviewed each slide using ordinary H & E stains and gave his or her diagnosis.
The

"experts" used

the classification scheme they were the proponent of, while

the "experienced” pathologists classified each

slide by each of

classifications.

to each pathologist

reliability.

Slides were also resubmitted

The diagnoses were

then correlated with clinical

the
to

test

information from

each case.
The major conclusion of the study (much to
that

"experts") was

"...all six classifications were valuable and comparable in

reproducibility and clinical correlations."
each system separated
good

the relief of the

to poor,

the patients

In addition,

into subgroups with varying prognoses,

and no system was superior

to any other in

study also confirmed

previous observations

nodular

architecture have a better prognosis

(follicular)

it was concluded

that

this regard.

that
from

This

those lymphomas which display a
than

those with a
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diffuse architecture.
formulation"

Finally,

from

the work done

for the classification of

morphologic criteria alone,

in

this

study,

a

the NHL was proposed which,

subdivides

the NHL into

ten groups.

"working
using

Sub-*

classifications are provided as a means by which translation can be made
between each of
reports and
6.

This

the six major systems

therapeutic

trials.

formulation makes

to facilitate comparison of clinical

This working

formulation is presented

in Table

no provision for B or T cell categories.

Summary of Classification Systems

It

should be clear by now that

scientifically accurate,
the NHL is

the

search

for an easy,

reproducible,

and prognostically relevant classification scheme

far from over.

The Rappaport system has been proven

prognostically significant but appears scientifically out-moded.
Collins classificaton,
appears difficult

while

to use at

including
the present

the latest
time.

developed by the NCI is a worthwhile attempt
translator"
already "old

but

since it does not

in immunologic

The
to

"working

provide a

include T or B cell

for

to be
The Lukesresearch,

formulation”

"universal

terminology it appears

fashioned".

The search for the
our knowledge of

"definitive"

immunology moves

understanding of normal
reclassify the lymphomas
biologic basis.

classification scheme will progress while

forward.

lymphocytes and
so

Ultimately a more

lymphomatous

that we will be able

ideal

cells will allow us

to

to design therapy on a purely
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Table 6.

WORKING FORMULATION OF NCI STUDY OF NHL CLASSIFICATION
LOW GRADE
A.

Small Lymphocytic

B.

- plasmacytoid
Follicular, small cleaved cells

- consistent with CLL

- diffuse areas
C.

- sclerosis
Follicular, mixed

small and

large cell

- diffuse areas
- sclerosis
INTERMEDIATE GRADE
D.

Follicular,

large cell

E.

- sclerosis
Diffuse, small cleaved cells

F.

- sclerosis
Diffuse, mixed

- diffuse areas

G.

small and

large cell

- sclerosis
- epithelioid cell component
Diffuse, large cell
- cleaved cell
- non-cleaved cell
- sclerosis

HIGH GRADE
H.

Large Cell,

immunoblastic

- plasmacytoid
- clear cell
- polymorphous
- epithelioid cell component
I.

J.

Lymphoblastic
- convoluted
- non-convoluted
Small Non-cleaved Cell
- Burkitt’s
- follicular areas

Miscellaneous
Composite
Mycosis Fungoides
Histiocytic
Extramedullary plasmacytoma
Unclassifiable
(Adapted

from NCI study of classifications of NHL (24))
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DIFFUSE HISTIOCYTIC LYMPHOMA

Diffuse Histiocytic Lymphoma (DHL) is one of the most common subtypes of
the Rappaport classification of the NHL, comprising about one third of all
non-Hodgkin's lymphomas.

Since it was originally described by Rappaport, DHL

gained the reputation as being a highly aggressive neoplasm that was refractory
to treatment (46).

However, over the last fifteen years great advances have

been made in its treatment, especially in the area of combination chemotherapy,
so that it is now considered a "potentially curable" neoplasm (47).

It has

been demonstrated that in actuality DHL is comprised of a group of neoplasms
with widely divergent histology, natural history, and response to treatment.
Complete response rates up to 69% have been achieved (48) but there remains a
large group that has proven to be unresponsive to treatment.

Many attempts

have been made to identify this sub-group in advance of treatment and
investigation continues to develop aggressive treatment for it.

The study

j

which follows is one such attempt.

Before the study is presented prognostic

factors in DHL will be discussed followed by a review of current treatments for
the disease.

Prognostic Factors in DHL

Site of Involvement:

Numerous studies have discussed site of primary

involvement as a prognostic factor in DHL.
can be drawn from these studies.

However no consistent conclusion

A retrospective review by Fisher et. al. (49)

identified gastrointestinal involvement and hepatic involvement as predictors

.
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of a poor prognosis
undifferentiated
involvement
(

10 cm),

for patients with diffuse histiocytic, mixed,

lymphomas.

Other studies however have discounted GI or liver

(50,51) as a poor prognostic

and involvement of

prognosis but

there appears

study by Strauchen (36)

factor.

Presence of a

"huge"*GI tumor

the CNS have similarly been correlated with poor
to be no consensus on this

issue

(36,

49-53).

A

indicated a high correlation between iramunoblastic

sarcomas and CNS and GI involvement which might account

for the occasional

finding of poor survival among patients with involvement at
Invasion of

or

the bone marrow seems

these sites.

to be correlated with poor prognosis and

this

Is supported by a number of studies (49-53).
Laboratory studies:

There is

is a predictor of poor survival

indication that

serum LDH

significant

(50).

This

study also

250 u/liter
that

A hemoglobin level of

12 mg/ml was identified as a predictor of poor prognosis

study (51).

y

(49) although some authors have suggested

levels above 500 U/liter are more
that

some

less

in one recent

found no correlation between Erythrocyte

Sedimentation Rate and prognosis.
Age/Sex:
not

Again the literature presents a mixed picture but age and sex do

seem to be correlated with survival.

was a poor prognostic factor

(49) while another found

years was correlated with poor survival
Stage:

However one study found

Theoretically,

and DHL in particular,

it has

Rosenberg (54) has suggested,

prognostic information,

2) assist

that age greater

sex

than 60

(51).

Staging of the NHL in general,

proven to be as clinically useful as

that male

has not

in Hodgkin's disease.
a staging system should 1)

the physician in selecting therapy,

provide a standardized system for international comparisons, and 4)

provide

3)

describe

'

*
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the extent of

the disease.

The Ann Arbor scheme

disease (see Table 7) has been applied
three of these goals.

It has

prognostic information.

not

to

for

the staging of Hodgkin's

the NHL and has

however,

supplied much

fulfilled
in

the way

the last

of

For example a patient with nodular poorly-

differentiated lymphocytic lymphoma may present with stage IV disease but may
run an indolent course,

while a patient with DHL may have a much poorer

prognosis

even though he/she may present with stage II disease.

suggested

that clinicians use a sequential

Arbor staging system while being aware
the determination of prognosis
Pathology:

Most

(55).

studies have

factor in determining prognosis
already been discussed,
indicated by a nodular

It

has been

staging scheme based on the Ann

that other factors weigh more heavily in
(See Table 8).

indicated

that

the single most

important

is pathological classification.

in the Rappaport classification,

a good

As

it has

prognosis

lymphoma or one composed of lymphocytes.

However

the

Rappaport classification make no attempt

to separate lymphomas of

histiocytic

The Lukes-Collins classification

divides

type

into different groups.

the DHL into

five categories which have been discussed.

to be some difference among these
still a controversial point.

five groups

is

the diffuse

There appears

in terms of prognosis

but

this

is

,
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Table 7.

ANN ARBOR STAGING CLASSIFICATION
Stage I
Involvement of a single lymph node region (I)
involvement of a single extranodal organ/site
Stage II

or localized
(Ie).

Involvement of more than one lymph node region on the same
side of the diaphragm (II) or of one or more lymph node regions
and localized involvement of an extralymphatic organ/site (lie)
on the same side of the diaphragm.
Stage III
Involvement of lymph node regions on both sides of

the

diaphragm (III) which may be accompanied by involvement of
the spleen (Ills) or by localized involvement of an
extralymphatic organ/site (Ille) or both (Illse).
Stage IV
Diffuse or disseminated involvement of one or more extra¬
lymphatic organ/site with or without lymph node involvement.

Table 8.

SEQUENTIAL STAGING OF NHL
Complete history and physical examination
Routine hematology and chemistries
Standard chest radiography
Metastatic skeletal survey
Isotopic bone/liver-spleen scanning
Bipedal

lymphangiography

Bone marrow biopsy
Percutaneous liver biopsy
Liver biopsies via peritoneoscopy
Staging laparotomy
(From Chabner et.

al.

(55))
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Treatment of Diffuse Histiocytic Lymphoma

Treatment of localized DHL

Approximately 20-30% of patients with DHL present with localized
or II)

disease.

Sweet and Golumb have recently reviewed

radiation therapy in localized DHL.
disease

they found that patients

months and an 11 yr.

their experience with

Treating 28 patients with stage I or II

with stage

survival of 72.5 months and a 93% 11 yr.
Patients with stage II disease

(Stage I

I disease achieved a median

actuarial disease

free survival.

fared much worse with a median survival of 33

actuarial survival of 33%.

disease with radiation therapy alone and
chemotherapy or chemotherapy alone

treat

Many centers now treat

stage I

stage II with adjuvant

(56).

Treatment of advanced DHL

The

treatment of advanced DHL (stages II-IV) has changed considerably in

the last decade.
poor prognosis,

Far

from the aggressive neoplasm which carried a uniformly

DHL is now considered a

"potentially curable" neoplasm.

agent chemotherapy in the sixties was disappointing,
remissions,

few complete

with 5-10% of patients achieving a complete remission and median

survival averaging less
vincristine,

producing

Single

than one year.

and prednisone)

affect survival
chemotherapy was

(48).
found

increased

Treatment with CVP (cyclophosphamide,
the complete remission rate but did not

In the early seventies aggressive combination
to be successful

in patients with Hodgkin's disease
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(nitrogen mustard, vincristine,

procarbazine,

and prednisone)

and using

cyclophosphamide in place of nitrogen mustard DeVita achieved a complete
♦

remission rate,

for patients with DHL,

remission was very durable,
free

for 26-105 months

of a rather low 50% but

that

this

91% of the complete responders remaining disease

(47).

In 1972 and 1975,

regimen called COMA (cyclophosphamide,
leucovorin,

found

and cytosine arabinoside)

researchers at Yale,

using a

vincristine, methotrexate with
reported

similar durable remissions

in

6/8 patients (57).
Since the advent of the newer antitumor antibiotics,
bleomycin,
devised.

numerous regimens
The

the efficacy of these drugs have been

trials of these newer combinations have been numerous and

details of each are beyond
reviewed

testing

adriamycin and

the scope of this

paper.

Sweet and Golomb have

the current status of the combination chemotherapy of DHL (48).

table giving the results of some of these studies can be seen
has proven difficult to compare the results of these studies
reasons.

First of all,

be the same,
Second,

even though the acronyms used

in Table 9.

A
It

for a number of

in different

studies may

the dosage and administration schedules are often different.

there are often differences

in restaging

achievement of a complete remission so
from one

the

study to another.

chemotherapy in addition to
the number of patients

that

In addition,
the initial

techniques done after

the meaning of remission may vary

some

studies

use maintenance

therapy while others do not.

in each study is often small making

Finally

statistical

significance difficult to achieve.
Since the review by Sweet and Golumb,

two new combinations of standard

chemotherapeutic agents have been published.

Laurence et.

al.

(58)

have
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reported

the results of a

study of a six-drug chemotherapy regimen called

COP-BLAM (cyclophosphamide, vincristine,

prednisone,

bleomycin,

doxorubicin and
f

procarbazine)

administered

to patients with stage III and IV DHL.

achieved a complete remission rate of 73% and partial
Median survival has not

yet been reached.

reported a trial of cyclophosphamide,
continuous

infusion of bleomycin,
regimens,
state

was an attempt

possible

The rationale

for

Complete remission rate

the continuous
in other

from this study

no prior chemotherapy while no

1) There are numerous chemotherapeutic

regimens using maintenance

than those without maintenance
after

vincristine combined with

from the data generated at

achieving complete remission in DHL,
3)

recently

patient

in

pulmonary toxicity (n=37).

A few conclusions are
centers;

(59)

to reduce pulmonary toxicity while keeping a steady

therapeutic level of bleomycin.

study developed

al.

rate of 24%.

rather than the bolus administration found

was 77% for DHL patients who had had
the

Ginsberg et.

doxorubicin,

infusion of low-dose bleomycin.

response

They

2)

that are

in

4)

produced more durable remissions

cures appear

to be

the achievement of a complete remission and patients

remission for two years appear

successful

remission rates vary between 41-69%,

therapy have not
therapy,

regimens

the various

to be cured of

their disease

possible only

remaining
(48).

in
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Table 9.

A COMPARISON OF CHEMOTHERAPEUTIC TREATMENT OF ADVANCED DHL
Complete
response rate %

Regimen

Comments

50% survival

f

COMA

75%

—

C-MOPP

41%

9

selected

series

restaged;

few relapses

after 2 yrs if CR
BACOP(NCI)
CHOP/HOP

48%

14

selected

series

68%/66%

23

+maintenance

BACOP(Farber)

56%

9

+maintenance

COMA

40%

9

selected

CHOP + Bleo

61%

COMLA

55%

+25

unselected

COP-BLAM

73%

+26

50% survival not

25(approx)

series

some with BCG

reached yet

C

= Cyclophosphamide

0
M
A

= Vincristine
= Methotrexate (ex C-MOPP where M=Nitrogen mustard)
= Cytosine arabinoside (ex COP-BLAM where A=Adriamycin)

P
= Prednisone
PP = Prednisone + Procarbazine
B
= Bleomycin (also BL)
H
L

= Adriamycin
= Leucovorin rescue
(adapted

from Sweet and Golomb (48))
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A RANDOMIZED TRIAL OF ACOMLA AND CHOP-BLEO IN ADVANCED DHL

t

Introduction to Study

A randomized trial of two chemotherapy treatments was initiated
with two main goals.

The first was

to compare

the efficacy of a new regimen

ACOMLA to that of a commonly used drug combination CHOP-Bleo
below)

for the treatment of advanced DHL.

Lukes-Collins classification was able
unresponsive to treatment so

that

prospectively and more aggressive

to

in 1975

(descriptions

The second goal was

to see

if

the

identify subsets of DHL that were

these subsets could be identified
treatments designed

for

them.

Individual Chemotherapeutic Agents

Cyclophosphamide (Cytoxan)

is an alkylating agent

that acts by inactivating

DNA, which may be administered both intravenously or orally.
cycle specific and causes most of its

Nausea, vomiting and

is an anthracycline antibiotic which binds DNA

permitting intercalation thus

impairing the

drug may only be given intravenously.

template activity of

drug extravasates during administration.
cardiomyopathy which may be
(60).

fatal,

the DNA.

The

Myelotoxicity is the major complication

and nausea, vomiting and alopecia are common.

than 500 mg/m2

Bone marrow

(60).

Doxorubicin (Adriamycin)

less

is not cell

toxicity during the S-phase.

suppression is common and is the limiting toxicity.
alopecia are common

It

Tissue necrosis can occur if

This drug causes an unusual

although death is rare with

the

form of

total dosage of
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Vincristine

(Oncovin)

periwinkle Vinca rosea.
to

inhibit

is a derivative of an alkaloid

found

in the

Its mechanism of action is not clearly defined but it

is

thought

the cell cycle at metaphase by damaging spindle ’protein.

It

is only administered intravenously and does not cause myelosuppression.

Neurotoxicity is common and reversible paresthesias may occur
Methotrexate is a folate antagonist
catalyzes

the reduction of dihydrofolate

this is inhibition of DNA synthesis.
death during the S-phase.

It

that acts by inhibiting
to

tetrahydrofolate.

the enzyme that
The result of

is cell cycle specific and causes cell

Leucovorin (folinic acid)

or intermediate dose methotrexate to decrease
renal crystal

(60).

formation, myleosuppression,

is administered after high

toxicity.

nausea,

Toxicity includes

vomiting and vasculitis

(60).
Cytosine Arabinoside (Cytarabine,
that has a structural alteration in
polymerase.

It

Ara-C)

is an analogue of deoxycytidine

the sugar moiety and acts by inhibiting DNA

is cell cycle specific acting during

the S-phase.

Its major

toxicity is myelosuppression (60).
Bleomycin is an agent isloated from Streptomyces verticillus which kills
dividing cells by causing chain
intravenously.

fragmentation of DNA.

It

is administered

Its most common toxicity is pulmonary fibrosis which generally

occurs at doses over 400 units.

The development of diffuse

interstitial

fibrosis can be anticipated by a decrease in diffusing capacity (60).
Prednisone is a corticosteroid which acts on neoplastic cells by an unknown
mechanism.

Side effects include GI bleeding,

alterations

in the psyche

(60).

electrolyte imbalances,

and
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The Therapeutic Regimens

The two chemotherapeutic regimens used in this study are called CfrOP-Bleo
and ACOMLA.

CHOP-Bleo has been used

since 1972 and has been reported

in a complete remission rate of 65% (61).
hydroxydaunorubicin,
evolved

vincristine,

al.

and

is reported

COMLA was developed
vincristine

prednisone and

bleomycin.

for tumor

cell kill during

the

COMLA was used by
(52).

the established agents cyclophosphamide and

lysis which was

then followed by methotrexate and

which kills cells

that are

period of rapid growth.

cytosine arabinoside have been shown
intracellular accumulation of

The ACOMLA regimen

to yield a complete remission rate of 55%

to utilize

cytosine arabinoside,

cross

It utilizes cyclophosphamide,

from COMLA with the addition of hydroxydaunorubicin.

Sweet et.

to result

synthesizing DNA,

for maximum

In addition, methotrexate and

to act synergistically by enhancing

the latter

(62).

The

latter two agents also

the blood-brain barrier which might help prevent

CNS relapses (63).

Materials and Methods

Between May 1976 and April 1982 patients were entered into Yale Human
Investigations
required

Committee protocol #1257

(approved May 26,

1976).

Conditions

for entry were:

1)

A diagnosis of diffuse histiocytic

lymphoma (Rappaport)

2)

Slides of original biopsy material

available

3)

Stage III or IV disease

for review at Yale

(Ann Arbor classification)
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4)

No previous chemotherapy

5)

Measurable disease (by physical exam or otherwise)

6)

Granulocyte count greater than 500 cells/mm3

7)

Platelet count greater than 50,000/mm3

8)

Age greater than 16 years

9)

Ability to give informed consent

(no upper limit)

Patients were not excluded with prior radiotherapy (unless
all sites known to have disease),

poor Karnovsky status,

this

included

or concurrent medical

illnesses.
All

patients received

the

following evaluation:

1)

Complete history and physical

2)

Complete blood count,

3)

Chest X-ray

4)

Bilateral

examination

liver and renal

(iliac crest)

function tests

bone marrow biopsy (with aspiration if

possible)
5)

Lymphangiography with intravenous pyelogram

6)

Gallium scan

7)

Liver-spleen scan

8)

Abdominal ultrasound,

CT scan,

GI series (if GI involvement or GI

symptoms)
9)

Lumbar puncture for cytology (if bone marrow involved)

10)

MUGA scan (if at risk for adriamycin cardiotoxicity)

11)

Pulmonary function tests

(if at risk for pulmonary toxicity)
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In addition,

original

classified according to

slides of biopsy material were reviewed blindly and

the Lukes-Collins classification.

Each patient was randomly (by coin-toss) assigned
ACOMLA treatment arms.

to either the CtfbP-B or

These treatments consisted of:

2
ACOMLA:

Adriamycin

40 mg/m

IV

Day 1

IV

Day 1

IV

Days

9

3 CYCLES

Cyclophosphamide

1 g/m

Vincristine

2 mg

1,8,15

Z

Methotrexate

120 mg/m

IV

Leucovorin

25 mg q6hx6

P0

Days 22,29,

2
Cytosine arabinoside

50,57,71
IV

300 mg/m
2

CHOP-Bleo:

Adriamycin

40 mg/m

IV

Day 1

9

9 CYCLES

Cyclophosphamide

1 mg/m

IV

Day 1

Vincristine

2 mg

IV

Days

IV

Days 1,5

PO

Days

Bleomycin

15 Units

1,5

9

Prednisone

100 mg/m

1,5

Each treatment lasted nine months (3 cycles of ACOMLA or 9 cycles of
CHOP-B).

Additional cycles were used when there was a question of persistent

disease.

Patients at risk for the toxic effects of chemotherapy were

identified and

treatment was reduced.

increased age,

2)

These patients were

identified by 1)

extensive radiotherapy or bone-marrow involvement,

elevated bilirubin,

4) history of heart

failure or arrythraias,

5)

3)

poor
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pulmonary function.

Dosages were modified according to Table 10,

for decreased

granulocyte count, nausea and vomiting, pulmonary fibrosis, diabetes mellitus,
history of psychosis, paresthesias, and muscle weakness.
One month after completion of therapy all patients were restaged using the
same procedures described in the initial evaluation.

If previous sites of

disease had clinical evidence of continued disease these sites were
re-biopsied.

Patients were then followed at two month intervals for two years

then followed at six month intervals.

A complete response (CR) was defined as

total disappearance of disease for one month after chemotherapy.

A partial

response (PR) was defined as a reduction in tumor size of at least 50% for at
least one month.
(NR).

Any response less than this was considered a non-response

Patients who failed to respond at all to chemotherapy were considered

indiction failures.

These were included in statistical analysis as

non-responders.
Survival was calculated from the date of protocol entry.

Freedom from

relapse was calculated from the date of objective CR to date of documented
relapse or date patient was last seen and known to have continued in CR after
reevaluation.

Most patients obtaining CR did so within two months of

initiation of therapy.

To eliminate observer subjectivity,

freedom from

relapse was also calculated for those acieving CR from the date therapy ended
to the same end point as previously mentioned.
unless otherwise stated.

This calculation was used

Survival was correlated with certain factors that

have been associated with prognosis.

These were: age, sex, size of mass,

presence of bone marrow involvement, CNS involvement,
Lukes-Collins pathology.
the Wilcoxon test.

GI involvement, and

Survival curves were calculated and compared using

1
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DOSE MODIFICATIONS

Table 10.
1.

Hematologic
a.

Regimen A
f

i. Decrease adriamycin and cyclophosphamide by 1/3 if the nadir
granulocyte count achieved

is

less

than 300/mm3

ii. Decrease MTX and cytosine arabinoside by 1/3 if WBC,
of

treatment,

less

is 2,500 to 3,500/mm3.

at

time

Omit dose if WBC is

than 2,500/mm3

iii. Decrease MTX by 40mg/m2 increments if WBC^L4,000/mm3
prior
b.

to dose.

Regimen B
i.

Decrease adriamycin and cyclophosphamide dose by 1/3 if
nadir granulocyte count after

previous dose

is

less

than

300/mm3.
ii.
2.

Wait 1 week if WBC <,3,000/mm3 at 3 weeks.

Other
a.

Cytosine Arabinoside - decrease

to 100mg/ra2 for protracted

unmanageable nausea and vomiting.
b.

Adramycin - limit total accumulative dose to 450mg/m2
(adriamycin + cyclophosphamide increases cardiotoxicity)

Omit

if bilirubin>3mg%.
c.

Bleomycin - limit

total accumulative dose

to 300mg total

(Pulmonary fibrosis occurs occasionally after
d.

Prednisone - omit

this dose)

if ulcer history or symptoms.

Omit

if

diabetes mellitus or history of psychosis.
e.

Vincristine - reduce 50% for severe paresthesias or unmanageable
constipation.
ileus.

f.

Omit

for profound muscle weakness,

Give only 1 mg total dose

foot drop or

for age65 yrs.

Methotrexate - do not escalate as outlined above if WBC not
>4,000/mm3.

Do not escalate if mucositis

present.
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Results

During

the study period,

patients were entered

into

between Kay,

the protocol.

analysis on pathology review,
histiocytic type.

1976 and April,

Another

Of

this part of

characteristics of
58.4 and

Of

than the diffuse

the remaining 48,

the analysis.

the patient

the

with

two did not have a

time of review so

they were

The median age

females

for

all

patients was

predominating.

CLINICAL CHARACTERISTICS BY LUKES-COLLINS PATHOLOGY
STAGE
//

III

SITES

IV

Sx

BM

GI

MASS
CNS

>10cm

REMISSIONS

Rx

CR

PR

NR

A

0

6

C

7

Lukes-Collins
lclFCC

13

4

9

4

4

1

0

1

8

4

7

5
8
4

2
4
4

0

2

0

0

1

0

7

5
1

0
0

3
4

6

3

3
2

3
1

6
5

4

1

3

0

0

0

8
5
4

8

8

2
5
4

0

0

3

IncFCC

14

B-IBS
T-IBS
LCU

2
0

1
1

lclFCC = large cleaved FCC

Rx A = ACOMLA

IncFCC = large non-cleaved FCC

Rx C = CHOP -B
= "B" symptoms
Sx

B-IBS
T-IBS
LCU

= B Cell immunoblastic sarcoma
= T Cell immunoblastic sarcoma
= large cell unclassified

Table 12.
Rx

CLINICAL CHARACTERISTICS BY TREATMENT
AGE
(mean)

SEX
M

STAGE
F

found

Tables 11 and 12 show the general

population.

the sex ratio was 28:20,

Table 11.

from

two were omitted because on review they were

Lukes-Collins classification specified at
from

a total of 54

4 were omitted

having lymphomas other

to have only stage I or II disease.

omitted

these,

1982,

SITES

III

IV

BM

GI

MASS
CNS

> 10cm

ACOMLA

59.1

12

8

4

16

6

3

0

3

CHOP-B

57.8

8

20

13

15

3

7

0

7

3
1
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ACOMLA vs.

Of

CHOP-B

the 48 patients,

CHOP-B.

treated with ACOMLA and 28 were

Of the ACOMLA patients one had not yet been restaged at

analysis and,
not

included

did

so during

although he was described as being
in the analysis.

in Table 13.
two

20 were

the first

in clinical

treate'd with
the

time of

remission,

he was

Most patients who achieved a complete remission

two months of

therapy.

The response

There was no significant difference

in response

rates are

listed

rates between

the

treatments.

RESPONSE RATES

Table 13.

CR

Rx

PR

NR

ACOMLA

13/19

(68%)

4/19

(21%)

2/19

(11%)

CHOP-B

20/28

(71%)

5/28

(18%)

3/28

(11%)

TOTAL

33/47

(70%)

9/47

(19%)

5/47

(11%)

Of

those patients achieving a complete response

had a relapse.

4 of these had bee

time to relapse ranged

a CR,

6 have died.

treated with ACOMLA and 3 with CHOP-B.

from 2 months

significant difference between the
Four of

their disease (2 ACOMLA,

there were 7 patients who

to 32 months (mean 10 months) with no

two

treatment arms.

Of

those

patients with

these died after a relapse with progression of

2 CHOP-B).

The

The other two deaths were apparently

■
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unrelated
while

to

their lymphoma.

One died a sudden death 8 months after

the other died with a pneumonia

The median survival

14 months after

Of

those patients who did not respond

less than 6 months.

Of

therapy.

for all patients has not yet been reached.

follow-up time is 32 months (37 for ACOMLA patients,
to

therapy

The* median

29 for CHOP-B patients).

therapy the median survival

time was

those patients who obtained only a partial response,

are alive on various chemotherapeutic agents while the median survival of

5

the

other 4 was 12 months.
Drug
ACOMLA,

toxicity was substantial.
1 CHOP-B).

decrease

There were

three drug-related deaths

Two patients developed bleomycin

in pulmonary function tests.

cardiotoxicity (1 ACOMLA,

2 CHOP-B).

the vincristine (1 ACOMLA,

5 CHOP-B).

(2

toxicity demonstrated by a

Three patients developed adriamycin
Six patients developed neurotoxicity from
There was a small difference

in sepsis

between the two

treatment arms with 37% of ACOMLA patients and 18% of CHOP-B

patients having

treatment-related

sepsis.

This difference was not significant

(p=0.17).

Prognostic factors

There was no correlation between the patients age,
tract involvement,
significant.
again,

not

or tumor size,

There was,

however,

and survival
a trend

that

stage IV patients

"randomized"

proved

to

to the ACOMLA treatment arm.

symptoms,

to be

for older patients

in a statistically significant manner.

clear there were more females

stage,

sex,

statistically

to do poorly,

For reasons

GI

but

that are not

the CHOP-B treatment arm and more
These differences were

48

significant.
survival,

However,

since neither age nor stage were correlated with

this had no effect on the study.

No patients

in the study had
t

involvement of

the CNS so this could not be analyzed as a prognostic

Nine patients (19%) presented with bone marrow involvement.
does not adversely affect survival
should be noted

that only one of

factor.

While this

in a statistically significant manner,

it

these patients has achieved a documented

complete remission and this patient had a relapse

two months after completion

of therapy.

has not been restaged.

Another is

in clinical remission but

others achieved a partial remission.

It

is

interesting

to note

patients with bone marrow involvement who attained a CR had
ACOMLA.

In view of

the

small numbers

involved

it would

that

the

The
two

been treated with

be unwarranted

to draw

any conclusions from this.
Table 10 shows
For analysis,
types)

and

decrease

the distribution of patients by Lukes-Collins pathology.

patients were grouped

"others"

in survival

(lclFCC,

into

IncFCC,

and

for patients with

there was no difference in relapse

immunoblastic

free survival.

sarcomas

carcinoma of

the

to survival.

The

first

treated with CHOP-B within one year of attaining CR.

with AML was diagnosed one month after completion of ACOMLA.
bladder cancer was diagnosed at
with excision.

the

same

time as

squamous

cell

acute myelogenous leukemia,

and grade I transitional cell cancer of the bladder.
in patients

but

There was no difference

types with regards

prostate,

There was a

(p=0.01)

There were four cases of patients with second malignancies:
carcinoma of the lung,

(T and B cell

large cell unclassified).

immunoblastic

between the FCC cleaved and non-cleaved

sarcomas

two were
The

found

patient

The case of

the lymphoma as was

treated
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Discussion

t

This
compare

study was originally designed

for two reasons.

the new regimen ACOMLA with CHOP-B in the

histiocytic

lymphoma.

classification)

The second was

that would be useful

prognosis and refractory to

to

The

first was

treatment of advanced diffuse

identify factors (eg.

in defining

to

that

Lukes-Collins

subset of DHL with a poor

treatment.

As was mentioned in the section on "treatment”
for several theoretical reasons.

the ACOMLA regimen evolved

The anti-metabolites methotrexate and

cytosine arabinoside are given after

tumor lysis to insure maximum cell kill

during the period of rebound growth.

Administration of cytosine arabinoside

after methotrexate has been shown to increase
In addition,
and

thus,

these

two drugs have been shown

intracellular concentration.

to cross

the blood-brain barrier

it is supposed, might help to prevent CNS relapses which have proven

to be problematic in other studies

(65).

The results of this study indicate that
between either
trend

its

treatment, measured by response rates and survival.

(not significant)

toward greater toxicity with ACOMLA.

whether or not ACOMLA was useful
this study.

there is no difference

in outcome
There

is a

The question of

in preventing CNS relapses was not answered by

There were only 9 patients who were at risk for a CNS relapse

(with bone marrow involvement)
complete remission.
marrow involvement and

It

is

and only one of

interesting to note

thus were at risk

It may be

that

in patients who had bone

for CNS relapse,

phosphamide and adriamycin was reduced by 33%
bone marrow suppression.

these attained a documented

the dosage of cyclo¬

(by protocol)

that with these patients

to avoid dangerous
the risk of bone
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marrow toxicity may have
remission and

give,

the desire

to attain a complete

the dosage should not be reduced.

There appears,
CHOP-B.

to be balanced against

then,

at

CHOP-B is cheaper

this

time,

no reason

($2700 for CHOP-B,

and has a slightly lower rate of

to recommend ACOMLA over

$3700 for ACOMLA),

toxicity,

easier

but ACOMLA may prove

more effective for patients with marrow involvement and uses a lower

to

to be
total

dosage of adriamycin.
The results of this study indicate
sex,

stage,

or presence of symptoms,

of patients with a poor prognosis.

that GI involvement,

were not useful in identifying

prognosis
trend

in one

however,

and

that

study but were not

is no apparent

explanation

included in the present one.

the one

There was a

to have difficulty in attaining

patient with a documented CR had a relapse

The number of patients with bone marrow involvement were
this was not a statistically significant

The ability of

the Lukes-Collins classification to

with varying prognoses

is currently a controversial

some studies find

prognosis than the

subset

Hematocrit and serum LDH levels were correlated with

a complete remission and

above,

There

for patients with bone marrow involvement

months later.

age,

This is in agreement with data from some

centers but is in disagreement with others.
for this difference.

tumor size,

that

small,

finding.
identify subsets of DHL

subject.

As was discussed

the large-cell FCC lymphomas have a better

immunoblastic

sarcomas,

while others dispute

this

finding.

Some studies have shown the large cleaved FCC lymphoma to have a better
prognosis
opposite.

than the large non-cleaved variety,

while one study reports

the

Still other studies have indicated no significant differences in

survival between any of

two

the large cell lymphomas.
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It is difficult

to explain why this controversy exists

in the literature.

There have been few studies that are prospective randomized

trials with the
f

patients given uniform treatment.

Sample sizes are

small which makes

difficult to compare results from different centers.

In addition,

it

there is the

apparent difficulty in using the Lukes-Collins classification which may result
in slight variances in interpretation of the histologic
there does

seem,

however,

to be a distinct

a better prognosis than the
current

series supports

iramunoblastic

this conclusion.

for

What this indicates is
his/her survival is

the FCC and

survival.

important

immunoblastic

indeed

Thus

to note

lymphomas was

it

found between
that

the

the

same.

remission

is apparent

that

the

identify a subset of DHL that carries

refractory to current

from this that a more efficacious
in order to

is

that once a patient achieves a complete

Lukes-Collins classification does

patients

It

to have

The results of this

There was no difference

independent of histology.

a poor prognosis and is

for the FCC lymphomas

sarcomas.

the cleaved and non-cleaved FCC lymphomas.
relapse-free survival

trend

subclassifications,

treatment.

It can be

treatment should be designed

induce a complete remission and

thus

inferred

for these

increase

their
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